• Huiqing Sun, Wei Qu, Guangjia Chen, Xiaonan Sun, Deqing Zhang, and Shichuan Shao.
• Tai'an City Central Hospital.
• Medicine (Baltimore). 2021 Jan 22; 100 (3): e24406.

BackgroundAtherosclerosis (AS), the predominant pathological basis of ischemic cardiovascular and cerebrovascular diseases, remains a common and severe clinical problem. The experiments in vitro and in vivo indicate that Traditional Chinese patent medicine (TCPM) shows beneficial efficacy against AS through a variety of mechanisms. However, the existing therapeutic TCPM for the treatment of AS are diverse, and it is still significant to evaluate the pros and cons of a certain TCPM. Therefore, the study aims to compare the efficacy and outcomes of different anti-atherosclerotic TCPM in adults with the hope of providing references for clinical decision making.MethodsCochrane Library, PubMed, Embase, Web of Science, China National Knowledge Infrastructure Database, Wanfang Database, Chinese BioMedical Literature Database, and China Science and Technology Journal Database will be searched. Randomized controlled trials (RCTs) of TCPM for aortic AS in adults will be included in this study if they meet the Population/Intervention/Comparison/Outcomes/Study Design (PICOS) criteria. Two reviewers will independently perform citations screening, data extraction and risk of bias assessment. STATA 15.0 and WinBUGS 1.4.3 will be employed to conduct statistical analyses under the Bayesian framework.ResultsThe efficacy and safety of various TCPM strategies on aortic AS in adults will be compared.ConclusionThe study will expand the range of options for anti-atherosclerotic therapeutic strategies and encourages further clinical research in traditional Chinese medicine.Inplasy Registration NumberINPLASY2020120036.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

25 keywords...

hide…